The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, lipid nanoparticle–mRNA formulations have been applied to produce therapeutic proteins or antibodies39,75,145,146, to edit virus genomes105 and to engineer immune cells136.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [105]
In the citing paper
“Gene-editing components can be delivered by lipid nanoparticle–mRNA formulations to treat genetic diseases, including HTI92,238, hypercholesterolaemia81,96,105,239, lipoprotein metabolism disorders85 and transthyretin amyloidosis239,240, which has been demonstrated in preclinical studies.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [105]
In the citing paper
“After i.v. injection of Cas9 mRNA TT3 LNPs following the injection of sgRNA TT3 LNPs, the PCSK9 protein level was remarkably decreased in C57BL/6 mice.[139]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [139]
In the citing paper
“Jiang et al. developed lipid-like nanoparticles for targeted delivery of Cas9 mRNA and sgRNA to the liver. This system achieved disruption of HBV DNA and the proprotein convertase subtilisin/kexin type 9 (pcsk9) gene in vivo [104].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering
Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.035 · Cited by 989
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 932
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Self-citationThe CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo
Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386
Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection
Yang, P. L., Althage, A., Chung, J., & Chisari, F. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202398599 · Cited by 381
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 312
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Self-citationTargeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 245
Self-citationZhen, S., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 215
HBVdb: a knowledge database for Hepatitis B Virus
Hayer, J., Jadeau, F., Deléage, G., Kay, A., Zoulim, F., & Combet, C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1022 · Cited by 212
Liu, X., Hao, R., Chen, S., Guo, D., & Chen, Y. Z. (2015) · Journal of General Virology · doi:10.1099/vir.0.000159 · Cited by 151
Qi, Z., Li, G., Hu, H., Yang, C., Zhang, X., Leng, Q., Xie, Y., Yu, D., Zhang, X., Gao, Y., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01024-14 · Cited by 110
Targeting hepatitis B virus cccDNA using CRISPR/Cas9
Kennedy, E. M., Kornepati, A. V. R., & Cullen, B. R. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.10.004 · Cited by 86
PCSK9 inhibitors and cardiovascular disease
Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 66
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Self-citationDrug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Metadata
- Authors
- Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X.
- Affiliations
- Center for Life Sciences (CN)
- The Ohio State University (US)
- Tsinghua University (CN)
- Corresponding author
- Dong, Yizhou
- Tan, Xu
- ORCID
- Venue
- Cell Research
- Published
- 2017-01-24
- Volume
- 27
- Issue
- 3
- Pages
- 440-443
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- PMC
- PMC5339835
- OpenAlex
- W2582215039
- Cited by
- 295
- References
- 15
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 24 · 2023: 34 · 2022: 49 · 2021: 35 · 2020: 37 · 2019: 36 · 2018: 40 · 2017: 17
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Ohio State University
- National PKU Alliance
- National Institute of General Medical Sciences (R35GM119679)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- CRISPR/Cas9, non-viral gene delivery, PCSK9, hypercholesterolemia, liver-targeted drug delivery, single guide RNA, in vivo gene editing
- MeSH terms
- Proprotein Convertase 9, CRISPR-Associated Protein 9, Animals, Base Sequence, DNA, Viral, Hepatitis B virus, Humans, Lipids, Liver, Mice, Inbred C57BL, Gene Targeting, NIH 3T3 Cells, Mice, Nanoparticles, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
